Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date.
Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH. Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs. A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule.
GHRP-2 binds and activates GHS-R1a, a Gq/11-coupled receptor expressed on pituitary somatotrophs and hypothalamic arcuate neurons. Receptor engagement triggers phospholipase C activation, inositol trisphosphate-mediated intracellular calcium mobilisation, and exocytosis of stored GH. Simultaneously, GHRP-2 potentiates the endogenous GHRH signal in the hypothalamus and partially suppresses somatostatin tone, producing a synergistic amplification of the pulsatile GH release that exceeds either pathway alone. Cortisol and prolactin secretion are also modestly elevated, reflecting broader GHS-R1a expression outside the somatotroph axis.
Human efficacy is unproven: no completed, published human efficacy RCT establishes that this compound works in people. All maturity below is literature volume and kind — never a verdict on effect. No completed, published human efficacy RCT — capped at Preclinical.
Indexed articles by era
Volume and kind of literature, over time.
pre-2010
2010-2019
2020-present
Across all eras, by kind
Animal / in-vitro1
Mechanistic1
Human0
Mechanism research coverage
Which pathways the research probes.
Does it actually work? — proven vs anecdotal
CitedM4A
Evidence quality varies by application and is graded below from cited literature. Anecdotal and community reports are not evidence of efficacy.
Strong humanLimited humanAnimal / in-vitroMechanisticAnecdotal only
Pharmacology
CitedM3
Evidence & literature
CitedM4
—indexed articles
0registered human trials
—last scanned
Reading the evidence
Evidence quality and gaps vary by application — see the cited grades above.
Indexed-article counts span all evidence tiers, not only completed human trials.
No first-party human-dosing, efficacy, or benefit claims are made here.
Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID:16352683 — COMPONENT-LEVEL, NOT BLEND-LEVEL — and specific to CJC-1295 WITH DAC (long-acting, albumin-binding), a DIFFERENT molecular entity from the short-acting no-DAC ("Mod GRF 1-29") form this blend's vendors actually sell. Primary randomized, placebo-controlled, double-blind ascending-dose human trial of DAC-form CJC-1295 monotherapy; half-life 5.8-8.1 d, IGF-I above baseline up to 28 d. This half-life does NOT apply to the no-DAC form used in this blend and is not asserted as a blend-level or no-DAC fact. Does not evaluate GHRP-2 or the combination.
No registered human trials found for this compound.
Status
No registered trials found
NEW
Routes of administration
How CJC-1295 & GHRP-2 Blend has been studied — pharmacology, not a protocol. RUO.
Dominant research route & oral stability
CitedRoutes
Dominant research route: No formal PK study of the CJC-1295 & GHRP-2 blend as a combined unit exists at any route. The CJC-1295 sold in this blend is consistently the short-acting no-DAC ("Mod GRF 1-29") form per vendor labeling — a materially different molecule from the long-acting DAC-conjugated CJC-1295 studied in Teichman et al. 2006 (half-life 5.8-8.1 d) and Ionescu et al. 2006 (albumin-binding half-life ~8 d), the only controlled human PK data for either CJC-1295 form. A 2026 narrative review (PMID 42395176) states the no-DAC form is essentially uncharacterised in peer-reviewed human literature, with no controlled human trials — no no-DAC-specific half-life (including the commonly-repeated, unsupported "~30 minute" vendor figure) is asserted here, fail-closed. GHRP-2/pralmorelin has its own separate oral-activity and GHSR-agonism literature (component-level, not blend-level) on the standalone compound datasheet.
Routes
No data availableNo route-of-administration research is on file for this compound yet.
4B · 10
Dosage reference & research tools
Dosage reference spectrum
UGC · disclaimedM4B
Figures are doses reported in studies (overwhelmingly animal — these do not translate to humans) or stated by vendors / community. Not medical advice. Not a recommendation for human use.
No data availableNo structured dosage-reference rows are on file yet.
Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.
Reconstitution calculator
UGC · disclaimedM10
mg
mL
Concentration
5.00 mg/mL
For a 250 mcg reference unitdraw 0.050 mL= 5.0 units (U-100)
Reconstituted stability22 of 28 days left
Research unit-conversion only · not for human use
07 · 08 · 24 · 34 · 35 · 33
Vendors & price intelligence
United States
Vendor & price comparison
CitedM7 · M8
Sorted A–Z by vendor — never by price
Median $/mg
$7.30
Range $4.50–$8.40
Vendors tracked
3
In stock
3
With COA
3
Weekly median · 5w
As of 2026-08-06· research-catalog listings, dated & cited — no ranking, no commission earned, never sorted by price. Research use only.
Vendor
Format · size
Price
Price / mg
COA
Stock
Source
BIBiotech Peptides
10 mgVial
$84.00
$8.40
2026-08-04
COCore Peptides
10 mgVial
$73.00
$7.30
2026-08-03
GEGenX Peptides
10 mgVial
$45.00
$4.50
2026-08-05
Crawled vendor listings, sorted A–Z by vendor — never by price.
Only the US market has been researched so far — no FX conversion is applied.
Vial-size economics
10 mg vial
5 vendors offer it
Bigger vials generally lower $/mg but raise reconstitution-waste risk.
Cost & value analytics
DerivedM24
Provisional · live crawl in progress
$8.00min /mg
$8.40median /mg
$9.50max /mg
Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.
Estimated cost of research (10 mg)
Vial (best researched price)
$80
Bacteriostatic water (generic estimate)
$6
Syringes / supplies (generic estimate)
$12
Vendor reliability
M34
No data availableOn-time / reship reliability metrics require the live crawl's fulfillment history, which is not collected yet.
Bulk / B2B procurement
M35
No data availableWholesale / vendor-direct pricing tiers are not researched yet.
Licensed clinics & 503A
CitedM33
Segregated from gray-market research vendors · shown only where lawful.
Opens as US reclassification formalizes
19 · 36 · 20 · 18 · 32
Quality, verification & alerts
Quality, testing & COA verification
CitedM19 · M36
What each test proves — general guidance, plus this compound's researched purity data
HPLC
Purity %
Mass spec (MS)
Identity — the only proof it is the right molecule
Potency / quantitation
Catches underdosing
Endotoxin (LAL)
EU/mg
Heavy metals
Contamination
Residual solvents
Process residue
Sterility / bioburden
Microbial
Lot / batch traceability
Provenance
Verify your vial's COA — paste a Janoshik task # to check authenticity & recency (< 6 mo).
Purity on the current market (researched)
Independent aggregate testing of CJC-1295 (no DAC — the form sold in this blend) across 53 vendors / 284 tests (Finnrick Analytics, Dec 2024-Jun 2026) showed purity varying from 1.69% to 100.00%, with quantity diverging up to ±100% vs advertised value. Of 200 listed tests: 61 pass, 139 fail (~69.5% fail rate). No blend-specific (CJC-1295+GHRP-2) aggregate purity range was identified; single-vendor COAs for the blend commonly claim ≥99%.
No recall specifically naming a CJC-1295 & GHRP-2 blend product was found. The ImprimisRx 2017 recall (PEG 40 castor oil/curcumin lots) and associated 2019 warning letter involved GHRP-2 compounding at the same firm but did not recall the GHRP-2 product itself. None found for the blend.
Buyer red-flag checklist
Neither CJC-1295 nor GHRP-2 is FDA-approved for any human use; both are unapproved new drugs when marketed for human use.
GHRP-2 is not on the FDA 503A bulks list and compounding with it has drawn 503A-ineligibility warning letters (per the 2019 United Pharmacy and ImprimisRx actions above).
CJC-1295 was removed from FDA Category 2 of the interim 503A bulks list in Sept 2024 after nominator withdrawal; regulatory status remains unresolved pending PCAC review.
Independent aggregate testing (Finnrick) shows CJC-1295 (no DAC) purity ranging as low as 1.69% and ~69.5% of tests failing pass criteria across 53 vendors — high prevalence of underdosing/impurity in the gray market.
FDA Import Alert 66-78 (general unapproved-new-drug import detention) exists, though a primary source confirming it names GHRP-2/GHRP-6/CJC-1295 individually could not be located this pass — treat any specific '12-peptide 2025 expansion' claim as unconfirmed, not a naming certainty.
Australia's TGA is reported (secondary sources; not independently confirmed this pass) to schedule GHRP-2, GHRP-6, and CJC-1295 as controlled substances, with import-without-permit penalties under Commonwealth law.
FDA FAERS reports include contamination in compounded versions and adverse events (infections, endocrine disruptions) per 2023-2026 FDA materials.
Single-vendor COAs commonly claim ≥99% purity, but independent aggregate data show wide variance — vendor self-reported purity should not be assumed accurate without third-party verification.
Manufacturing, grade & supply chain
CitedM18
GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.
Underdosing / mislabeling: Finnrick Analytics aggregate (CJC-1295, no DAC; 200 tests through Jun 2026): 139 of 200 tests failed Finnrick's pass criteria (purity/dose/label), a ~69.5% aggregate fail rate. Quantity can diverge up to ±100% vs advertised. This figure is for CJC-1295 (no DAC) alone, not the CJC-1295+GHRP-2 blend; blend-specific underdosing prevalence is not separately published.
Shipping, customs & landed cost
CitedM32
FDA Import Alert 66-78 (import detention of unapproved new drugs) is a real, standing alert. A primary FDA source could not be confirmed this pass naming GHRP-2, GHRP-6, or CJC-1295 individually, or documenting a specific 2025 twelve-peptide expansion — that compound-specific detail is unverified and not asserted as confirmed fact (mirrors the same hedge already applied to Import Alert 66-41 for the bpc-157-kpv-blend and cjc-1295-hexarelin-blend overlays). Both CJC-1295 and GHRP-2 are unapproved new drugs with no FDA-approved human indication, so import detention under the alert's general unapproved-new-drug basis remains plausible regardless of specific naming. An RUO label is not an importation exemption; FDA/CBP judge actual marketed/intended use.66-78 (compound-specific naming unconfirmed)
An RUO label is not an import exemption — CBP judges actual intended use.
Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.
06 · 6A · 31 · 44
Regulatory & developments
United States
Regulatory status & timeline
CitedM6
United States: Research use only. Regulatory detail for this region is not available in the current seed.
2004
Pralmorelin (GHRP-2) approved in Japan by PMDA as a diagnostic agent for growth hormone deficiency assessment (Kaken Pharmaceutical); not approved by FDA in the US. [PeptideInsight] (secondary source)
2023
CJC-1295 placed on FDA Category 2 of the interim 503A bulks list, identifying significant safety concerns and prohibiting traditional pharmacy compounding. [CJC-1295 Legal] (secondary source)
2023-09-29
GHRP-2 (for injectable and nasal routes) added to FDA 503B Category 2; FDA cited immunogenicity risk, peptide-related impurities, an unnatural amino acid, and reports of serious adverse events including increased insulin requirement, death of critically ill study subjects, infection and pancreatitis (causality not established). [FDA - Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks]
2024-09-20
FDA announced removal of CJC-1295 (along with AOD-9604, ipamorelin acetate, thymosin alpha-1, and Selank acetate) from Category 2 of the interim 503A bulks list after the nominators withdrew their nominations. [OnHealthcare.tech] (secondary source)
2024-09-27
Removal of CJC-1295 from Category 2 effective (seven days after FDA published its notice). [PeptideVerdict] (secondary source)
2024-10-25
Federal Register notice published (89 FR 85219) establishing PCAC meeting docket No. FDA-2024-N-4777 for public comment on bulk drug substances nominated for the 503A list; meeting held December 4, 2024. [Federal Register]
2024-12-04
Pharmacy Compounding Advisory Committee (PCAC) meeting held to evaluate nominated bulk drug substances including CJC-1295-related substances for potential inclusion on the 503A bulks list. [Federal Register]
2025-05-21
FDA-classified Class II recall (classified 2025-06-20) of a compounded CJC-1295 Injectable (6mg/15mg pre-filled syringes; lots H261968, H261358; 60 syringes) by Thrive Health and Wellness LLC dba Thrive Health Solutions (Englewood, CO), reason: lack of assurance of sterility. Names only CJC-1295 (no GHRP-2) and concerns a licensed-pharmacy compounded product, not the research-market blend. [HMP Global / Pharmacy Learning Network]
2026-01-01Current
WADA 2026 Prohibited List effective; GHRP-2 (pralmorelin) listed under S2.2 Peptide Hormones and Their Releasing Factors; CJC-1295 prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), in- and out-of-competition. [WADA 2026 Prohibited List (PDF)]
2026-04Current
FDA issued a warning letter (MARCS-CMS 720707) to Hangzhou Yiqi Biotechnology Co. (Chinese API producer of bulk peptides including CJC-1295) for major sterility/CGMP violations and added the firm to an import alert restricting its products' entry into the US. [FDA Warning Letters]
2026-07Upcoming
PCAC scheduled to review additional peptides for potential 503A bulk drug substances list inclusion; HHS indicated CJC-1295 may return to Category 1 while GHRP-2/6 likely remain restricted. [Pharmacy Times] (secondary source)
2026-07 · regulatory · Pharmacy Times · secondary source
WADA anti-doping status
CitedWADA
Prohibited at all times (in- and out-of-competition). GHRP-2 (pralmorelin) listed under S2.2 Peptide Hormones and Their Releasing Factors; CJC-1295 prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) on the 2026 WADA Prohibited List. A component-level classification — the blend itself has no independent WADA listing.
No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.
Use-context & responsibility
CitedM44
IACUC / IRB research context
RUO buyer responsibilities & documentation
Veterinary / alternative-use where lawful
Jurisdiction-aware "who may lawfully obtain"
12 · 17 · 22 · 39 · 13 · 11 · 23
Community, sentiment & answers
FAQ
CitedM13
Community sentiment
UGC · disclaimedM22
Research-seeded estimate — the tone mix is manually researched; contribution counts are illustrative until the live pipeline arms.
Community signal · Layer BDivided receptionHow it's received in discussion — not whether it works.
58/100
Positive 45%Neutral 30%Critical 25%
Based on 40 qualifying contributions across 2 platforms, last 90 daysModerate signal
Not enough history to show a trend yet.
What this is — and is not
Is
A read on how this compound is received in public discussion — the balance of positive, neutral and critical mentions over time.
Is not
Not a measure of whether it works, is safe, or is effective; not medical advice; the unverified opinions of anonymous community members (Layer B).
Community Sentiment — Layer B. This reflects the tone of public discussion across Reddit, Bluesky, YouTube and X over the last 90 days (as of 2025-10). It measures how a compound is discussed and received, not whether it is safe, effective, or appropriate for any use. It is not medical, dosing, or purchasing advice and is not an endorsement. Posts are aggregated and de-identified; individual comments, claims, and dosing discussion are never shown. Research use only.
Community themes & reported concerns
Research-seeded · not liveUGC · disclaimedM12 · M39
What people discuss
Sleep quality and recovery reports
22
Body composition / fullness / fat-loss reports
20
DAC vs no-DAC formulation debate
14
Stacking with Ipamorelin / Tesamorelin / other GHRPs
12
Sourcing and vendor third-party testing discussion
12
Dosing protocol and timing discussion
10
Cortisol elevation with GHRP-2 discussion
10
Reported concerns — discussion, not established effects
Water retention / edema reported in discussion
30%
Increased hunger reported in discussion
25%
Numbness / tingling in extremities reported in discussion
20%
Cortisol elevation / sleep disruption reported in discussion
20%
Injection-site reactions reported in discussion
15%
Headache / facial flushing reported in discussion
12%
Acute adverse-reaction events reported in discussion
10%
Reading caveats
Self-reported uncontrolled anecdotes
Bodybuilding-community overrepresentation
Vendor-affiliated posters present in threads
Survivorship bias toward positive reports
Conflation of CJC-1295 with DAC vs no-DAC across threads — this blend's CJC-1295 is the short-acting no-DAC ('Mod GRF 1-29') form; the community's DAC/no-DAC confusion is reported here as a discussion theme, not resolved as fact
Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.
41 · 21 · 42 · 28 · 27 · 26 · 29 · 43 · 14 · 16
Tools, market & meta
Research & market activity
M21
Relative research / market volume — populated once the activity stream is wired
No data availableA per-compound research and market activity stream is not collected yet.
Ask this datasheet
CitedM41
Grounded only in this compound's cited data · refuses dosing advice
Watch & listing momentum
M21
No data availableWatch and listing momentum derive from the vendor crawl, not yet wired for this compound.
Lifecycle & market history
M42
No data availableMarket lifecycle and price history are not collected for this compound yet.
Data confidence & contribute
CitedM28
VerifiedVendor-statedCommunityStale
Glossary & reading mode
CitedM27
Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.
Toggle plain-language ↔ scientific in the header.
Guides & explainers
CitedM26
How to read a COA
Free base vs acetate
Understanding evidence grades
Market intelligence
M43
No data availableCategory sizing and demand intelligence are not collected for this compound yet.
Citable summary (GEO)
DerivedM14
A research blend combining the GHRH analog CJC-1295 with the growth-hormone secretagogue GHRP-2. US regulatory status: Research use only. Research use only.
Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.